Notice for venetoclax (Abbvie Pty Ltd)
Active ingredients
venetoclax
Sponsor
Date of review outcome
Lapse date
Type
Orphan drug
Dosage form(s)
Tablet, film-coated
Indication
Venetoclax is indicated for the treatment of patients with acute myeloid leukaemia (AML)
Therapeutic area
Haematology